The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma

详细信息    查看全文

• 作者：Eun Jung Lee ; Jeong Hoon Kim ; Eun Suk Park ; Shin Kwang Khang…
• 关键词：Central nervous system ; Hemangiopericytoma ; Radiotherapy ; Survival ; Recurrence ; Metastasis
• 刊名：Journal of Neuro-Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：127
• 期：1
• 页码：181-190
• 全文大小：810 KB
• 参考文献：1.Chan RC, Thompson GB (1984) Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg 60:52–60. doi:10.​3171/​jns.​1984.​60.​1.​0052 CrossRef PubMed
  2.Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:514–522CrossRef PubMed
  3.Jaaskelainen J, Servo A, Haltia M, Wahlstrom T, Valtonen S (1985) Intracranial hemangiopericytoma: radiology, surgery, radiotherapy, and outcome in 21 patients. Surg Neurol 23:227–236CrossRef PubMed
  4.Kim JH, Jung HW, Kim YS, Kim CJ, Hwang SK, Paek SH, Kim DG, Kwun BD (2003) Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 59:47–53 discussion 53-44 CrossRef PubMed
  5.Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI, Bruce JN (2014) The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a surveillance, epidemiology, and end results analysis. J Neurosurg 120:300–308. doi:10.​3171/​2013.​10.​JNS13113 CrossRef PubMed
  6.Vuorinen V, Sallinen P, Haapasalo H, Visakorpi T, Kallio M, Jaaskelainen J (1996) Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir 138:1399–1408CrossRef PubMed
  7.Staples JJ, Robinson RA, Wen BC, Hussey DH (1990) Hemangiopericytoma—the role of radiotherapy. Int J Radiat Oncol Biol Phys 19:445–451. doi:10.​1089/​ten.​2005.​11.​985 CrossRef PubMed
  8.Schiariti M, Goetz P, El-Maghraby H, Tailor J, Kitchen N (2011) Hemangiopericytoma: long-term outcome revisited. J Neurosurg 114:747–755. doi:10.​3171/​2010.​6.​JNS091660 CrossRef PubMed
  9.Ghia AJ, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery 72:203–209. doi:10.​1227/​NEU.​0b013e31827b9e68​ CrossRef PubMed
  10.Stessin AM, Sison C, Nieto J, Raifu M, Li B (2013) The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma-experience from the SEER database. Int J Radiat Oncol Biol Phys 85:784–790. doi:10.​1016/​j.​ijrobp.​2012.​05.​042 CrossRef PubMed
  11.Ghia AJ, Chang EL, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma: patterns of failure and the role of radiation therapy. Neurosurgery 73:624–630. doi:10.​1227/​NEU.​0000000000000064​ discussion 630-621 CrossRef PubMed
  12.Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH (2004) Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer 100:1491–1497. doi:10.​1002/​cncr.​20109 CrossRef PubMed
  13.Giannini C, Rushing E, Hainfellner J (2007) Haemangiopericytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon
  14.Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.​1007/​s00401-007-0243-4 PubMedCentral CrossRef PubMed
  15.National cancer institute (2010) Common terminology criteria for adverse events (CTCAE) v.4 data files. http://​evs.​nci.​nih.​gov/​ftp1/​CTCAE/​About.​html . Accessed 8 December 2015
  16.Melone AG, D’Elia A, Santoro F, Salvati M, Delfini R, Cantore G, Santoro A (2014) Intracranial hemangiopericytoma—our experience in 30 years: a series of 43 cases and review of the literature. World Neurosurg 81:556–562. doi:10.​1016/​j.​wneu.​2013.​11.​009 CrossRef PubMed
  17.Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2012) Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:1628–1636. doi:10.​1002/​cncr.​26411 CrossRef PubMed
  18.Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, Mills SA, Barani IJ, Parsa AT (2010) Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg 113:333–339. doi:10.​3171/​2010.​3.​JNS091882 CrossRef PubMed
  19.Olson C, Yen CP, Schlesinger D, Sheehan J (2010) Radiosurgery for intracranial hemangiopericytomas: outcomes after initial and repeat Gamma Knife surgery. J Neurosurg 112:133–139. doi:10.​3171/​2009.​3.​JNS0923 CrossRef PubMed
  20.Rutkowski MJ, Bloch O, Jian BJ, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2011) Management of recurrent intracranial hemangiopericytoma. J Clin Neurosci 18:1500–1504. doi:10.​1016/​j.​jocn.​2011.​04.​009 CrossRef PubMed
  21.Ecker RD, Marsh WR, Pollock BE, Kurtkaya-Yapicier O, McClelland R, Scheithauer BW, Buckner JC (2003) Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patients. J Neurosurg 98:1182–1187. doi:10.​3171/​jns.​2003.​98.​6.​1182 CrossRef PubMed
  22.Fountas KN, Kapsalaki E, Kassam M, Feltes CH, Dimopoulos VG, Robinson JS, Smith JR (2006) Management of intracranial meningeal hemangiopericytomas: outcome and experience. Neurosurg Rev 29:145–153. doi:10.​1007/​s10143-005-0001-9 CrossRef PubMed
  23.Damodaran O, Robbins P, Knuckey N, Bynevelt M, Wong G, Lee G (2014) Primary intracranial haemangiopericytoma: comparison of survival outcomes and metastatic potential in WHO grade II and III variants. J Clin Neurosci 21:1310–1314. doi:10.​1016/​j.​jocn.​2013.​11.​026 CrossRef PubMed
  24.Rajaram V, Brat DJ, Perry A (2004) Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol 35:1413–1418. doi:10.​1016/​j.​humpath.​2004.​07.​017 CrossRef PubMed
  25.Trabelsi S, Mama N, Chourabi M, Mastouri MH, Ladib M, Popov S, Burford A, Mokni M, Tlili K, Krifa H, Jones C, Yacoubi MT, Saad A, Brahim DH (2015) Meningeal hemangiopericytomas and meningomas: a comparative immunohistochemical and genetic study. Asian Pac J Cancer Prev 16:6871–6876CrossRef PubMed
  26.Zhao P, Zhu T, Tang Q, Liu H, Zhu J, Zhang W (2015) Immunohistochemical and genetic markers to distinguish hemangiopericytoma and meningioma. Int J Clin Exp Med 8:3291–3299PubMedCentral PubMed
  27.Perry A, Scheithauer BW, Nascimento AG (1997) The immunophenotypic spectrum of meningeal hemangiopericytoma: a comparison with fibrous meningioma and solitary fibrous tumor of meninges. Am J Surg Pathol 21:1354–1360CrossRef PubMed
  28.Alawi F, Stratton D, Freedman PD (2001) Solitary fibrous tumor of the oral soft tissues: a clinicopathologic and immunohistochemical study of 16 cases. Am J Surg Pathol 25:900–910CrossRef PubMed
  29.Chaubal A, Paetau A, Zoltick P, Miettinen M (1994) CD34 immunoreactivity in nervous system tumors. Acta Neuropathol 88:454–458CrossRef PubMed
  30.Bouvier C, Metellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, Mokhtari K, Varlet P, Dufour H, Figarella-Branger D (2012) Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol 22:511–521. doi:10.​1111/​j.​1750-3639.​2011.​00552.​x CrossRef PubMed
  31.Macagno N, Figarella-Branger D, Mokthari K, Metellus P, Jouvet A, Vasiljevic A, Loundou A, Bouvier C (2015) Differential diagnosis of meningeal SFT-HPC and meningioma: which immunohistochemical markers should be used. Am J Surg Pathol. doi:10.​1097/​PAS.​0000000000000526​
  32.Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45:131–132. doi:10.​1038/​ng.​2522 PubMedCentral CrossRef PubMed
  33.Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, Brosjo O, Domanski HA, Larsson O, Sciot R, Debiec-Rychter M, Hornick JL, Mandahl N, Nord KH, Mertens F (2013) Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosom Cancer 52:873–886. doi:10.​1002/​gcc.​22083 CrossRef PubMed
  34.Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:180–185. doi:10.​1038/​ng.​2509 PubMedCentral CrossRef PubMed
  35.Fletcher CDM, Unni KK, Mertens F (2002) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon
  36.Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Gock T, Jones DT, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, Konig R, Wiestler OD, Pfister SM, von Deimling A (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:651–658. doi:10.​1007/​s00401-013-1117-6 CrossRef PubMed
  37.Barthelmess S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A, Haller F (2014) Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 184:1209–1218. doi:10.​1016/​j.​ajpath.​2013.​12.​016 CrossRef PubMed
  38.Koelsche C, Schweizer L, Renner M, Warth A, Jones DT, Sahm F, Reuss DE, Capper D, Knosel T, Schulz B, Petersen I, Ulrich A, Renker EK, Lehner B, Pfister SM, Schirmacher P, von Deimling A, Mechtersheimer G (2014) Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology 65:613–622. doi:10.​1111/​his.​12431 CrossRef PubMed
  
• 作者单位：Eun Jung Lee (1)
  Jeong Hoon Kim (1)
  Eun Suk Park (2)
  Shin Kwang Khang (3)
  Young Hyun Cho (1)
  Seok Ho Hong (1)
  Chang Jin Kim (1)
  
  1. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Olympic-ro 43-gil 88, Songpa-gu, Seoul, 05505, Korea
  2. Department of Neurosurgery, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwando-ro, Dong-gu, Ulsan, 44033, Korea
  3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Olympic-ro 43-gil 88, Songpa-gu, Seoul, 05505, Korea
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

Because of the rarity of intracranial hemangiopericytomas (HPCs), the role of postoperative radiation therapy (PORT) in the management of HPC remains unclear. This study therefore analyzed the effects of PORT on patterns of failure and survival improvement in patients with HPC. Fifty-two patients surgically treated for intracranial HPC at our institution between 1992 and 2013 were retrospectively analyzed. Patterns of failure were subdivided into local recurrence, regional metastasis, and distant metastasis. Multivariate Cox proportional hazards models were used to assess factors prognostic of treatment failure and survival, and a time-dependent Cox proportional hazards models were used to investigate the correlations between patterns of failure and death. Of the 52 patients, 45 (87 %) underwent gross total resection, and 39 (75 %) received PORT. PORT significantly lengthened local control (LC) and overall survival (OS), by 14 and 13 months, respectively, independent of the extent of resection. Patients who did and did not receive PORT had 5 year LC rates of 97 and 44 %, respectively (HR .05, P = .002); and 10 year OS rates of 83 and 25 %, respectively (hazard ratio (HR) .20, P = .008). PORT, however, did not show preventive effects on regional and distant metastases. The main patterns of failure were local recurrence in patients who did not receive PORT and distant metastasis in those who received PORT. Regional metastasis was a main immediate cause of death (P < .001), and tended to occur more frequently and earlier in patients not receiving PORT.